Skip to main content
. 2021 Jan 4;12(1):8. doi: 10.1038/s41419-020-03308-w

Fig. 1. Combination of verteporfin-NP, paclitaxel-NP, and/or combretastatin-NP suppressed both bulk tumor cells and cancer stem cells.

Fig. 1

A The viability of TNBC MDA-MB-231 cells was determined by MTT assay after 120-hr treatment with E-NP (empty-nanoparticle), P-NP (paclitaxel-NP, 5 nM), V-NP (verteporfin-NP, 250 nM), C-NP (combretastatin-NP, 5 nM), or different combinations. B Tumorsphere (TS) formation, an in vitro assay indicating cancer stem cells (CSCs) after different treatments with drug-NPs. MDA-MB-231 cells overexpressing E-cadherin were grown in low attachment and serum-free conditions, and treated for 120 hrs as described in A, followed by MTT viability assay. C Representative photographs of TS shown in B. Data represent means ± SD, *P < 0.05, **P < 0.01, ****P < 0.001.